Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity

Molecular Therapy

Volumn 17, Issue 6, 2009, Pages 980-991

  Manfredsson, Fredric P ^a   Tumer, Nihal ^a,b   Erdos, Benedek ^a,b   Landa, Tessa ^a,b   Broxson, Christopher S ^a,b   Sullivan, Layla F ^a   Rising, Aaron C ^a   Foust, Kevin D ^a   Zhang, Yi ^a,b   Muzyczka, Nicholas ^c   Gorbatyuk, Oleg S ^c   Scarpace, Philip J ^a,b   Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE Y; NORADRENALIN; OXYTOCIN; PARVOVIRUS VECTOR;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG EFFICACY; FOOD INTAKE; GENE ACTIVATION; GENE OVEREXPRESSION; HYPOTHALAMUS; INTERMETHOD COMPARISON; MALE; MESENCEPHALON; MOTOR ACTIVITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; NUCLEUS ACCUMBENS; OBESITY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; THALAMUS MIDLINE NUCLEUS; TRANSGENE; VIRAL GENE THERAPY; WEIGHT REDUCTION;

ADIPOSITY; AGING; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPENDOVIRUS; DOPAMINE; EATING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MALE; NEUROPEPTIDE Y; OBESITY; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; WEIGHT LOSS;

ADENO-ASSOCIATED VIRUS; PRIMATES; RATTUS;

EID: 67349113221     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.45     Document Type: Article

References (49)

1. Lin, LF, Doherty, DH, Lile, JD, Bektesh, S and Collins, F (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
2. Pascual, A, Hidalgo-Figueroa, M, Piruat, JI, Pintado, CO, Gomez-Diaz, R and Lopez- Barneo, J (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761.
3. Bespalov, MM and Saarma, M (2007). GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28: 68-74.
4. Jing, S, Wen, D, Yu, Y, Holst, PL, Luo, Y, Fang, M, et al. (1996). GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 85: 1113-1124.
5. Treanor, JJ, Goodman, L, de Sauvage, F, Stone, DM, Poulsen, KT, Beck, CD, et al. (1996). Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83.
6. Trupp, M, Scott, R, Whittemore, SR and Ibanez, CF (1999). Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274: 20885-20894.
7. Mograbi, B, Bocciardi, R, Bourget, I, Busca, R, Rochet, N, Farahi-Far, D et al. (2001). Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: Importance for the rescue of neuroectodermic cells. J Biol Chem 276: 45307-45319.
8. Zigmond, MJ (2006). Triggering endogenous neuroprotective mechanisms in Parkinson's disease: Studies with a cellular model. J Neural Transm Suppl 439-442.
9. Golden, JP, DeMaro, JA, Osborne, PA, Milbrandt, J and Johnson, EM Jr (1999). Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158: 504-528.
10. Zhang, Z, Miyoshi, Y, Lapchak, PA, Collins, F, Hilt, D, Lebel, C, et al. (1997). Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282: 1396-1401.
11. Kordower, JH, Palfi, S, Chen, EY, Ma, SY, Sendera, T, Cochran, EJ et al. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
12. Nutt, JG, Burchiel, KJ, Comella, CL, Jankovic, J, Lang, AE, Laws, ER Jr et al. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
13. Patel, NK, Bunnage, M, Plaha, P, Svendsen, CN, Heywood, P and Gill, SS (2005). Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 57: 298-302.
14. Slevin, JT, Gash, DM, Smith, CD, Gerhardt, GA, Kryscio, R, Chebrolu, H, et al. (2007). Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: Response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106: 614-620.
15. Tumer, N, Scarpace, PJ, Dogan, MD, Broxson, CS, Matheny, M, Yurek, DM, et al. (2006). Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity. Neurobiol Aging 27: 459-470.
16. Lindvall, O and Bjorklund, A (1978). Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 19: 1-23.
17. Ungerstedt, U (1971). Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 95-122.
18. Sotak, BN, Hnasko, TS, Robinson, S, Kremer, EJ and Palmiter, RD (2005). Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res 1061: 88-96.
19. Szczypka, MS, Kwok, K, Brot, MD, Marck, BT, Matsumoto, AM, Donahue, BA, et al. (2001). Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30: 819-828.
20. Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S, et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317.
21. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700.
22. Gorbatyuk, OS, Milner, TA, Wang, G, Regunathan, S and Reis, DJ (2001). Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei. Exp Neurol 171: 235-245.
23. Khan, AM, Ponzio, TA, Sanchez-Watts, G, Stanley, BG, Hatton, GI and Watts, AG (2007). Catecholaminergic control of mitogen-activated protein kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro: A proposed role during glycemic challenges. J Neurosci 27: 7344-7360.
24. Georgievska, B, Kirik, D and Bjorklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474.
25. Aoi, M, Date, I, Tomita, S and Ohmoto, T (2000). The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: Behavioral and histological studies using two different dosages. Neurosci Res 36: 319-325.
26. Hoane, MR, Gulwadi, AG, Morrison, S, Hovanesian, G, Lindner, MD and Tao, W (1999). Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 160: 235-243.
27. Lapchak, PA, Jiao, S, Collins, F and Miller, PJ (1997). Glial cell line-derived neurotrophic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 747 92-102.
28. Gash, DM, Zhang, Z, Cass, WA, Ovadia, A, Simmerman, L, Martin, D, et al. (1995). Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 363 345-358.
29. Horger, BA, Nishimura, MC, Armanini, MP, Wang, LC, Poulsen, KT, Rosenblad, C, et al. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18: 4929-4937.
30. Palmiter, RD (2007). Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30: 375-381.
31. Li, H, Matheny, M, Nicolson, M, Tumer, N and Scarpace, PJ (1997). Leptin gene expression increases with age independent of increasing adiposity in rats. Diabetes 46: 2035-2039.
32. Bassareo, V and Di Chiara, G (1999). Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments. Neuroscience 89: 637-641.
33. Hernandez, L and Hoebel, BG (1988). Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. Physiol Behav 44 599-606.
34. Martel, P and Fantino, M (1996). Mesolimbic dopaminergic system activity as a function of food reward: A microdialysis study. Pharmacol Biochem Behav 53: 221-226.
35. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15: 1504-1511.
36. Rosenblad, C, Georgievska, B and Kirik, D (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17: 260-270.
37. Morton, GJ, Cummings, DE, Baskin, DG, Barsh, GS and Schwartz, MW (2006). Central nervous system control of food intake and body weight. Nature 443: 289-295.
38. Liu, HS, Jan, MS, Chou, CK, Chen, PH and Ke, NJ (1999). Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun 260: 712-717.
39. Detrait, ER, Bowers, WJ, Halterman, MW, Giuliano, RE, Bennice, L, Federoff, HJ, et al. (2002). Reporter gene transfer induces apoptosis in primary cortical neurons. Mol Ther 5: 723-730.
40. Kirik, D, Rosenblad, C, Burger, C, Lundberg, C, Johansen, TE, Muzyczka, N, et al. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
41. Klein, RL, Dayton, RD, Leidenheimer, NJ, Jansen, K, Golde, TE and Zweig, RM (2006). Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13: 517-527.
42. Isacson, O and Kordower, JH (2008). Future of cell and gene therapies for Parkinson's disease. Ann Neurol 64: S122-S138.
43. Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L, et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 767-773.
44. Eslamboli, A, Georgievska, B, Ridley, RM, Baker, HF, Muzyczka, N, Burger, C, et al. (2005). Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25: 769-777.
45. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 158-167.
46. Ben-Barak, Y, Russell, JT, Whitnall, M, Ozato, K and Gainer, H (1984). Phylogenetic cross-reactivities of monoclonal antibodies produced against rat neurophysin. Cell Mol Neurobiol 4: 339-349.
47. Erdem, SR, Demirel, HA, Broxson, CS, Nankova, BB, Sabban, EL and Tumer, N (2002). Effect of exercise on mRNA expression of select adrenal medullary catecholamine biosynthetic enzymes. J Appl Physiol 93 463-468.
48. Manfredsson, FP, Burger, C, Sullivan, LF, Muzyczka, N, Lewin, AS and Mandel, RJ (2007). rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 207: 289-301.
49. Swanson, LW (1999). Brain Maps: Structure of the Rat Brain, 2nd edn. Elsevier: Amsterdam.